PNR Pharma was founded in 2012 and has become a well-respected pharmaceutical services provider in the UK and European Union offering Qualified Person (QP), Quality Assurance and Supply Chain solutions for investigational and marketed medicinal products. The company has achieved strong growth and success by adhering to their core values of excellence, expertise, and customer-centricity and they have established a strong presence in the industry, earning the trust of clients worldwide. With a strong network of QPs and supply chain specialists, PNR Pharma delivers customised support for traditional, biologic, biotech, vaccine, plasma and advanced therapies throughout their lifecycle, offering tailored expertise from Phase I through to commercialisation, ensuring regulatory compliance at every stage. Their fully licensed UK warehouse provides storage and global distribution of commercial and clinical trial supplies, as well as packaging and labelling of investigational medicinal products. Core Services: • GMP/GDP audits to support QP Declarations • Importation and QP certification of clinical trial and commercial products • Secondary packaging and labelling of clinical trial supplies • Controlled temperature storage and global distribution of certified batches • Batch review, including bulk confirmation • Regulatory inspection readiness preparation • Site remediation support • Training of key personnel in UK/EU GMP and GDP requirements • CMC section review of Investigational Medicinal Product Dossiers (IMPDs) or Common Technical Documents (CTDs)
PlasmidFactory GmbH
PlasmidFactory GmbH, established in 2000 in Bielefeld, Germany, is a premier contract development and manufacturing organization specializing in plasmid and minicircle DNA. We support clients and partners in cancer research, gene and cell therapy, and vaccination, with a focus on CAR-T cell development, AAV gene transfer, and minicircle tools for mRNA synthesis. We offer custom plasmid and minicircle DNA manufacturing services across various quality grades from Research and CCC grade up to High Quality grade and GMP certified material for clinical trials and applications. Our state-of-the-art facilities fulfil the highest quality standards, with full GMP services launching in Q4, 2025. Our extensive In-Stock product range supports immediate research needs, including AAV production plasmids and reporter constructs. At the forefront of Next Generation Gene Vectors, our R&D focuses on advancing our proprietary minicircle DNA technologies. Through strategic collaborations with global partners, we are committed to pioneering solutions for academia and the biopharmaceutical industry. – 25 years CDMO experience and innovation in plasmid and minicircle DNA – +3000 successful projects – From research grade to GMP – Talk to us to discuss how we can support your projects in the area of CGT, AAV or mRNA | PlasmidFactory GmbH, established in 2000 in Bielefeld, Germany, is a premier contract development and manufacturing organization specializing in plasmid and minicircle DNA. We support clients and partners in cancer research, gene and cell therapy, and vaccination, with a focus on CAR-T cell development, AAV gene transfer, and minicircle tools for mRNA synthesis. We offer custom plasmid and minicircle DNA manufacturing services across various quality grades from Research and CCC grade up to High Quality grade and GMP certified material for clinical trials and applications. Our state-of-the-art facilities fulfil the highest quality standards, with full GMP services launched in 2025. Our extensive In-Stock product range supports immediate research needs, including AAV production plasmids and reporter constructs. At the forefront of Next Generation Gene Vectors, our R&D focuses on advancing our proprietary minicircle DNA technologies. Through strategic collaborations with global partners, we are committed to pioneering solutions for academia and the biopharmaceutical industry. – 25 years CDMO experience and innovation in plasmid and minicircle DNA – +3000 successful projects – From research grade to GMP – Talk to us to discuss how we can support your projects in the area of CGT, AAV or mRNA
Piramal Pharma Solutions
PPS is a Contract Development and Manufacturing Organization (CDMO) offering end-to-end development and manufacturing solutions across the drug life cycle. We serve our customers through a globally integrated network of facilities in North America, Europe, and Asia. This enables us to offer a comprehensive range of services including drug discovery solutions, process & pharmaceutical development services, clinical trial supplies, commercial supply of APIs, and finished dosage forms. We also offer specialized services such as the development and manufacture of highly potent APIs, antibody-drug conjugations, sterile fill/finish, peptide products & services, and potent solid oral drug product.PPS also offers development and manufacturing services for biologics including vaccines, gene therapies, and monoclonal antibodies, made possible through Piramal Pharma Limited’s investment in Yapan Bio Private Limited. Our track record as a trusted service provider with experience across varied technologies makes us a partner of choice for innovator and generic companies worldwide. | Piramal Pharma Solutions (PPS) is a Contract Development and Manufacturing Organization (CDMO) offering end-to-end development and manufacturing solutions across the drug life cycle. We serve our customers through a globally integrated network of facilities in North America, Europe, and Asia. This enables us to offer a comprehensive range of services including drug discovery solutions, process and pharmaceutical development services, clinical trial supplies, commercial supply of APIs, and finished dosage forms. We also offer specialized services such as the development and manufacture of highly potent APIs, antibody-drug conjugations, sterile fill/finish, peptide products and services, and potent solid oral drug products. PPS also offers development and manufacturing services for biologics including vaccines and gene therapies, made possible through Piramal Pharma Limited’s associate company, Yapan Bio Private Limited.
Pii (Pharmaceutics International, Inc.), A Jabil Company
Pii (Pharmaceutics International, Inc.), A Jabil Company, is a drug product Contract Development and Manufacturing Organization (CDMO) that provides custom solutions for complex aseptic, parenteral, and oral dosage forms. Founded in 1994, Pii has grown from its oral solid dosage (OSD) roots to offer solutions from concept through clinical to full commercialization, including aseptic manufacturing, lyophilization, analytical testing, and robotic filling. Based in Hunt Valley, MD, Pii delivers phase-appropriate solutions for the most challenging drug formulations, potent compounds, and controlled substances, supporting small to medium-volume projects with unmatched flexibility and transparency. With an unwavering commitment to our clients, our mission is to prioritize complex and niche life-saving therapies that often get sidelined. We partner with these companies to bring their innovations to market—on time, every time. Discover more at www.pharm-int.com.
PharmaResources(Shanghai) Co., Ltd.
PharmaResources, established in 2007, is a comprehensive one-stop service provider for new drug R&D as well as commercial production. We are dedicated to the drug discovery, pharmaceutical processes R&D, and the commercial manufacturing of APIs and intermediates | PharmaResources, established in 2007, is a comprehensive one-stop service provider for new drug R&D as well as commercial production. We are dedicated to the drug discovery, pharmaceutical processes R&D, and the commercial manufacturing of APIs and intermediates. Our new drug R&D services cover the entire process of preclinical new drug research, primarily including drug discovery and processR&D. In drug discovery, we assist clients in designing, screening, and optimizing hit compounds and lead compounds , conducting structural improvements, and preliminary safety screening to obtain candidate compounds with outstanding drug properties and intellectual property rights.In our process R&D servicewe provide new drug process chemistry services and innovative synthetic process development for global pharmaceutical companies,helping clients to achieve cost-effective, safe, green, and reliable commercial manufacturing of intermediates and APIs in scales from kilograms to tons. Leveraging our technological advantages in pharmaceutical process technology, we also engage in the customized manufacturing services of key drug intermediates,as well as independent research and development and manufacturing of specialty APIs intermediates with complex chemical structures and high synthesis difficulties. In March 2021, PharmaResources’ IPO application for GEM was accepted by the Shenzhen Stock Exchange. In April 2022, it successfully passed the review of the Listing Committee of the Shenzhen Stock Exchange.On July 8, 2022, the China Securities Regulatory Commission approved the application of PharmaResources (Shanghai) Co.,Ltd. for an initial public offering of stocks and listing on the Shenzhen GEM. On October 18, 2022, PharmaResources issued 19.25 million A-shares in its initial public offering and was listed on the GEM. As advocated in the core values of PharmaResources, ‘Science-driven, continuous innovation’.Regardless of how the internal and external environment may change, ‘Science and Innovation’ is the perpetual goals of our team. Only by consistently pursuing scientific excellence and technological innovation can we meet the ever-changing needs of our clients and the market, while ensuring the sustainable competitiveness of our company.
Pharmascience
Pharmascience, founded in 1983, is a manufacturer of high quality generic products. Our fully integrated Canadian specialty division, Pendopharm, is a leader in commercializing innovative and value-added medicines that address unmet medical needs across key therapeutic areas. With an impressive annual production of over 5 billion doses and distribution spanning more than 50 countries, we offer 1,300 distinct high-quality products in various dosage forms. Additionally, our services extend to sterile injectable CDMO (Contract Development and Manufacturing Organization) for both the Canadian and international markets. Thanks to substantial investments totaling $150 million, we have tripled our sterile injectable capacity, enabling us to provide a comprehensive range of services for prefilled syringes, liquid vials, and lyophilized vials. We eagerly look forward to connecting with you, whether in person or through the partnering app! | Since 1983, Pharmascience has been a leading manufacturer of generic, branded, and over-the-counter pharmaceuticals, serving both the Canadian and international markets. With product distribution in over 50 countries, we provide more than 1,400 different high-quality products to pharmaceutical wholesalers, hospitals, and pharmacists. Our facilities produce more than 5 billion dosage units of medicines every year.
Phage Consultants
Phage Consultants is a company specializing in bacteriophage problems troubleshooting and prevention. It was founded in 2007 based on many years of experience in this field of its founder. Company, among other phage prevention- and troubleshooting-related activities, provides RCB, WCB and MCB testing for the presence of virulent phages and inducible prophages, also in strict anaerobes. Most probably, we have the greatest experience in this field on the whole global market. | PHAGE CONSULTANTS specializes in prevention and troubleshooting of phage contamination problems in various production and laboratory setups through a variety of services. We offer phage detection and identification services, facility audits and initial assessments, consultations, personnel training, advice on bioprocess optimization and SOP improvement, and new facility development. We also offer fast and reliable routine or as-required testing of incoming bacterial strains and cell banks for the presence of both lytic phages and prophages – a necessary tool in phage prevention. With these services, Phage Consultants can help you avoid phage contaminations and recover quickly from contaminations that have already occurred. | We are a company specializing in phage contamination troubleshooting and prevention with 18 years of experience on the market. We helped to solve over 200 cases of phage contamination in production facilities and research labs. Among the other activities, we provide RCB, WCB and MCB testing for the presence of virulent phages and inducible prophages, also in very unusual hosts like strict anaerobes. Such tests are very important in order to provide smooth production process and to avoid any problems with ready product. We also provide contract research in any field of phage use, which may be also the modification and fine tuning of microbiome. If our activity is anyhow interesting for you, I would be delighted to schedule a meeting with your representative.
Parque Pharma / Helix
PARQUE PHARMA + HELIX Where Infrastructure Meets Execution In life sciences, speed, compliance, and control often conflict. Companies must choose: build and wait years, outsource and lose visibility, or buy risk. These tradeoffs drain capital, erode margin, and delay impact. Parque Pharma and Helix eliminate that tradeoff. We offer a single-entry platform into Mexico and Latin America—combining GMP-ready infrastructure and regulatory-commercial execution in one seamless model. Two Forces. One Outcome. Parque Pharma Mexico’s first and only pharmaceutical condominium model, delivering turnkey, validated GMP facilities with shared infrastructure. No CapEx. No permitting delays. Just speed, certainty, and full regulatory alignment (COFEPRIS, FDA, EMA, USDA). Helix A strategic execution system for health, designed to compress timelines and reduce friction. From product registration to facility activation and market expansion, Helix integrates regulation, operations, and commercial logic. Together, we make GMP execution plug-and-play. What We Offer GMP facility leasing (with option to buy) COFEPRIS / FDA / EMA regulatory navigation Product registration and local compliance GMP validation & audit readiness Licensing, M&A support, and market launch Operational strategy for long-term scaling Why It Works Speed to Market Installations ready in 10 months or less—with fast-track validation pathways. Regulatory Clarity Certified cleanrooms. No licensing delays. No retrofit risk. Zero CapEx, Maximum Flexibility Lease Class A, spec-built facilities designed for pharma, biotech, supplements, and veterinary use. Execution Certainty Validated systems. Turnkey delivery. Compliance built-in. Ideal For… Biotech companies expanding into Latin America Pharma looking to escape CMO bottlenecks Brands needing dual COFEPRIS + SENASICA certification Supplement companies requiring FDA-grade local ops CDMOs seeking flexible GMP-certified space Let’s Connect at BIO 2025 If you’re scaling in Mexico or LatAm— Let’s turn compliance and construction into momentum.
Parimer Scientific
Drug Development Parimer collaborates with emerging biotechnology companies in their early-stage development and clinical trial manufacturing. Parimer has supported over 25 similar companies in the last several years to bring their biotechnology to the commercial market. Parimer is compliant with ICHQ7 standards, licensed, and accredited for cGMP manufacturing for human use. | Parimer Scientific: Precision Chemistry, Relentless Execution Parimer Scientific is a privately held contract development and manufacturing organization (CDMO) based in South Carolina, USA. We specialize in helping life science innovators bring complex products to market with speed, precision, and regulatory confidence. Our team is intentionally small—lean, focused, and deeply invested in the success of every project we take on. We are not a traditional CDMO. We are a hands-on, execution-first partner that integrates directly into your development pipeline. Our scientists and engineers work shoulder-to-shoulder with clients, taking ownership of outcomes and delivering results with urgency and pride. With minimal executive overhead and no layers of bureaucracy, we move fast, communicate clearly, and stay accountable from kickoff to commercialization. We also navigate the regulatory landscape with confidence, maintaining ISO, USP, and FDA compliance through rigorous audits and certifications. Over the past decade, Parimer has supported the successful commercialization of more than a dozen biotech innovations. Our clients range from early-stage startups to multinational pharmaceutical companies, and our work spans APIs, medical devices, biologics, and specialty chemicals. Whether you need a kilo of GMP material, a regulatory-ready CMC package, or a custom polymer for a combination product, we deliver with rigor and reliability. Parimer’s core strength lies in chemistry. Our team of PhD- and MS-level chemists brings deep expertise in synthetic organic chemistry, analytical chemistry, and chemical engineering. We support projects from milligram-scale R&D to kilo-scale GMP manufacturing, with a focus on speed, flexibility, and compliance. We develop and scale active pharmaceutical ingredients (APIs) for clinical and commercial use, including CNS-active agents, transdermal compounds, deuterated analogs of active compounds, and controlled substances under DEA Schedule I–V. In the medical device space, we formulate and manufacture polymeric components and excipients for Class I and II devices, including bioresorbable polymers, custom polymeric excipients for drug-device combination products, and hydrogels and elastomers for implantable systems. Our biologics and complex molecule capabilities include the development and manufacturing of polysaccharides such as USP-grade chitosan, adjuvants for vaccine formulations, and recombinant proteins, peptides, and oligonucleotides. We also serve adjacent industries with specialty and agricultural chemical projects, including extraction and purification from marine biomass and analytical method development for agrochemical compounds. Parimer excels in custom chemistry and route development. We routinely perform reverse engineering, route scouting, and purification of complex mixtures, and we specialize in developing scalable synthetic routes for rare or unstable intermediates. Our in-house analytical suite includes HPLC, GC, FTIR, GPC, UV-Vis, DSC, ICP-MS, ROI, and LOD, along with microbial and bioscreening assays. For advanced techniques such as NMR, SEM, XRD, and XRF, we collaborate with trusted local partners. To further enhance our capabilities, Parimer integrates artificial intelligence into our workflows. Predictive modeling tools help us optimize synthetic routes, forecast stability profiles, and identify potential impurities before they arise. These tools empower our scientists to focus on high-value problem-solving and innovation. Our ISO-accredited, GMP-compliant cleanroom facility is licensed by the DEA and FDA to handle all schedules of drug classifications. We are NSF-accredited under ISO 9001 and audited annually to ensure the highest standards of quality and compliance. Designed for flexibility, our facility allows us to pivot quickly between projects while maintaining rigorous documentation and traceability. We maintain a 95%+ on-time delivery rate and are committed to transparency, precision, and continuous improvement. Our project managers are incentivized to deliver under budget and ahead of schedule, and our quality systems are built to scale with your needs. We understand that our clients entrust us with their most sensitive intellectual property. Confidentiality is not just a policy—it’s a pillar of our culture. All projects are governed by strict NDAs, and our facility is designed with secure data handling protocols, restricted access zones, and audit-ready documentation systems. We have never had a breach of client confidentiality, and we intend to keep it that way. At Parimer, we don’t just complete tasks—we take ownership. Every member of our team is empowered to make decisions, solve problems, and drive projects forward. We are passionate about science, obsessed with quality, and relentless in our pursuit of results. Our size is our strength. We are nimble, responsive, and personally invested in every project we take on. We don’t hide behind process—we lead with purpose.
PAN-Biotech GmbH
PAN-Biotech is your trusted partner for OEM and CMO solutions in the biotech industry. With over 30 years of experience, we offer high-quality cell culture media, sera, and custom manufacturing sterile liquid solutions. Benefit from our expertise and expand your business in Europe with a reliable partner by your side. • Manufacturing (OEM, CMO, CDMO) • Upstream / Downstream • R&D for Cell Culture • Tailored Logistic Solutions Products & Services Our core strength is our flexibility, which enables us to provide customized solutions to partners in research and industry. This includes state-of-the-art cell culture products for research and preclinical applications, all manufactured according to ISO 13485. For clinical applications, we facilitate a seamless transition from RUO (Research Use Only) to EU GMP Annex 1, thereby supporting easy access to commercialization. Gateway to Europe with PAN-Biotech At PAN-Biotech, we understand the challenges when setting foot on a new continent. We are here to assist you every step of the way. From manufacturing and product storage to delivering your products to new customers, we provide comprehensive support to help you achieve your goals. | PAN-Biotech offers high-quality cell culture media, sera, and custom manufacturing sterile liquid solutions. This includes state-of-the-art cell culture products for research and preclinical applications, all manufactured according to ISO 13485. For clinical and industrial applications, we offer GMP grade products in accordance with GMP EU Annex 1.